ACET Stock Forecast: Adicet Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Adicet Bio, Inc. is $24. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Adicet Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ACET stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ACET, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Guggenheim | Maintains | Buy | $90 → $55 |
| 29 Sept 2026 | Wedbush | Maintains | Outperform | $25 → $28 |
| 28 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $27 → $34 |
| 18 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $27 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $100 → $90 |
| 5 May 2026 | Jefferies | Assumes | Buy | $8.00 → $19 |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 21 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Jan 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Oct 2025 | Guggenheim | Maintains | Buy | — |
| 19 Sept 2025 | Guggenheim | Reiterates | Buy | — |
| 23 July 2025 | HC Wainwright & Co. | Assumes | Buy | $4.00 |
| 21 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 7 Mar 2025 | Citizens Capital Markets | Reiterates | Market Perform | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 27 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 6 Feb 2025 | JMP Securities | Reiterates | Market Perform | — |
| 5 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACET.
This page is one stock. Monday covers all of them.
ACET appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ACET vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Adicet Bio, Inc. returned −76.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ACET analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −85.9%
- Return on assets
- −44.3%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Adicet Bio, Inc. has a market value of $23.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$99.0M.
Diluted earnings per share, trailing twelve months: −$11.45.
Free cash flow in the twelve months to 30 June 2026: −$85.0M.
Adicet Bio, Inc. employs 102 people.
Data provided by Twelve Data
ACET and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ACET’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Adicet Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ACET
What is the ACET stock price forecast for 2026-2027?
The median 12-month analyst price target for Adicet Bio, Inc. is $24, with estimates ranging from $18 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ACET stock a buy right now?
Of the 6 analysts covering Adicet Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adicet Bio, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ACET?
As at 21 Nov 2026, Adicet Bio, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
Will ACET stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $24, and Ticker Nerd's factor model ranks Adicet Bio, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ACET stock forecast for 2030?
No analyst covering Adicet Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACET are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $55 over the next 12 months.
How has ACET stock performed over the past year?
Adicet Bio, Inc. returned -76.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Adicet Bio, Inc. do?
Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications.
About Adicet Bio, Inc.
Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications. Adicet Bio’s research and development efforts are aimed at advancing differentiated cell therapy candidates that combine immune-cell engineering with tumor-targeting or disease-modifying mechanisms. The company operates within the biotechnology and health technology sectors, where its programs contribute to the broader development of next-generation immunotherapies for patients with serious and difficult-to-treat conditions. Adicet Bio is headquartered in Boston, Massachusetts.
CEO Mr. Chen Schor BA, C.P.A., M.B.A. · 102 employees · United States · https://www.adicetbio.com